More on 2024 MS diagnostic criteria at the Mellen Update 2025:
@DanOntaneda
provided an overview, while I presented the application. +other excellent lectures from the same event
@mssociety@ACTRIMS@ECTRIMS#MultipleSclerosis LINK https://t.co/oIVZYCzJTC
Congratulations to @Karl0CB for a successful defense of his PhD. An honor to be his advisor. Getting a PhD in Residency and Fellowship is no small feat 5 papers will come from his thesis. Important work that helped get CVS in DXcriteria @ClevelandClinic@BlakeBuletko@CLENeurons
New studies point to potential for greater reliance on objective imaging biomarkers for accurate diagnosis of multiple sclerosis: https://t.co/whGjU8lVCW
@GavinGiovannoni Of note, in this recent Swedish retrospective NS cohort, definite NS was associated with 7/14 having positive OCB. https://t.co/uMCD34hCLQ
Tools of the trade!
Last official day of residency at @CLENeurons@ClevelandClinic
Looking back at some numbers over 2 senior years; patients I have encountered during inpatient rotations:
- nights: 201
- acute stroke: 177
- 24h call: 117
- consult: 111
- gen neuro: 84
- stroke: 61
- neurohospitalist: 59
- NICU: 55
- epilepsy: 54
- pediatric: 35
= 954
+ as a moonlighter: 139
+ many more in clinic and as a jr resident
This was excellent work done by @Karl0CB in the NAIMS CAVS-MS pilot team effort with @PascalSati@takishinohara@danielsaloreich and Andy Solomon. Also our prospective multi center study is fully enrolled!
This year ECTRIMS is ensuring the latest MS research unveiled at our congress reaches the entire #MS community. The ECTRIMS 2022: For People with MS Event is now available for viewing in English, Dutch, French, German, Italian & Spanish.
Watch it now ➡️ https://t.co/GHq9cP6aiY